Flanigan R C, Yonover P M
Department of Urology, Loyola University Medical Center, Maywood, IL 60153-5500, USA.
Semin Urol Oncol. 2001 May;19(2):98-102.
The role of cytoreductive surgery in patients with metastatic renal cancer remains controversial. Recent data from our Southwest Oncology Group trial suggest that cytoreduction confers an approximately 50% increase in median survival for such patients when they are treated with interferon-alfa-2b immunotherapy. The timing of cytoreduction, and in which patients it may be most applicable, are discussed herein.
减瘤手术在转移性肾癌患者中的作用仍存在争议。我们西南肿瘤协作组试验的最新数据表明,对于接受α-2b干扰素免疫治疗的此类患者,减瘤手术可使中位生存期提高约50%。本文讨论了减瘤手术的时机以及最适合接受该手术的患者类型。